Raludotatug deruxtecan

德瑞鲁妥塔单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameRaludotatug deruxtecan
Drug Alias NameDS-6000aDS6000aDS-6000R-DXdMK-5909
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-Cadherin-6
TargetsDNA topoisomerase ICadherin-6
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdDaiichi Sankyo IncDaiichi Sankyo Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A